FDA’s Acting Chief Scientist Offers Vaccine Continuity As Goodman Departs
This article was originally published in The Pink Sheet Daily
Jesse Goodman will become director of Georgetown University’s new Center on Medical Product Access, Safety and Stewardship while Stephen Ostroff steps up as FDA’s Acting Chief Scientist.
You may also be interested in...
While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.
Margaret Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in the House 21st Century Cures discussion draft would mandate a similar process always be followed.
Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she leaves the agency in March with high drug approval numbers, initiatives to improve the OTC monograph and switch programs and increased enforcement in the supplement manufacturing arena.